AR043272A1 - Una microparticula recubierta con una sustancia lipofilica que contiene una droga proteica o antigeno y formulaciones que la comprenden - Google Patents

Una microparticula recubierta con una sustancia lipofilica que contiene una droga proteica o antigeno y formulaciones que la comprenden

Info

Publication number
AR043272A1
AR043272A1 ARP000100211A ARP000100211A AR043272A1 AR 043272 A1 AR043272 A1 AR 043272A1 AR P000100211 A ARP000100211 A AR P000100211A AR P000100211 A ARP000100211 A AR P000100211A AR 043272 A1 AR043272 A1 AR 043272A1
Authority
AR
Argentina
Prior art keywords
microparticle
lipofilica
proteic
formulations
understand
Prior art date
Application number
ARP000100211A
Other languages
English (en)
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019990001232A external-priority patent/KR100329336B1/ko
Priority claimed from KR1019990059776A external-priority patent/KR100359252B1/ko
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of AR043272A1 publication Critical patent/AR043272A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una micropartícula lipofílica que tiene un tamano de partícula promedio de 0,1 a 200 um, micropartícula que comprende una sustancia lipofílica y un ingrediente activo seleccionado del grupo formado por una droga proteica y un antígeno, reteniendo dicha partícula la actividad completa del ingrediente activo, y al ser formulada en la forma de una dispersión en aceite o una emulsión de aceite en agua, libera en un ambiente in vivo el ingrediente activo de un modo controlado durante un período prolongado.
ARP000100211A 1999-01-18 2000-01-18 Una microparticula recubierta con una sustancia lipofilica que contiene una droga proteica o antigeno y formulaciones que la comprenden AR043272A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019990001232A KR100329336B1 (ko) 1999-01-18 1999-01-18 히아루론산을 이용한 단백질 약물의 서방성 미세 입자 제형
KR1019990059776A KR100359252B1 (ko) 1999-12-21 1999-12-21 항원을 포함하는 고체상 미세입자 및 이를 포함하는 제제

Publications (1)

Publication Number Publication Date
AR043272A1 true AR043272A1 (es) 2005-07-27

Family

ID=26634599

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100211A AR043272A1 (es) 1999-01-18 2000-01-18 Una microparticula recubierta con una sustancia lipofilica que contiene una droga proteica o antigeno y formulaciones que la comprenden

Country Status (20)

Country Link
EP (2) EP1071407B1 (es)
JP (1) JP3802348B2 (es)
CN (1) CN1142772C (es)
AR (1) AR043272A1 (es)
AU (1) AU751200B2 (es)
BG (1) BG65233B1 (es)
BR (1) BR0004152A (es)
CA (1) CA2324403C (es)
DK (1) DK1071407T3 (es)
ES (1) ES2505696T3 (es)
HK (1) HK1036415A1 (es)
HU (1) HUP0101040A3 (es)
ID (1) ID25592A (es)
IL (1) IL138468A0 (es)
MY (1) MY125541A (es)
NZ (1) NZ506975A (es)
PL (1) PL200954B1 (es)
TR (1) TR200002683T1 (es)
TW (1) TWI260988B (es)
WO (1) WO2000041682A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
CN1174741C (zh) * 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
AU2006201100B2 (en) * 1999-09-21 2009-09-24 Jagotec Ag Surface modified particulate compositions of biologically active substances
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
WO2001093837A2 (en) * 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
US6998393B2 (en) * 2000-06-23 2006-02-14 Biopharm Solutions, Inc. Aquespheres, their preparation and uses thereof
CA2454920C (en) * 2001-07-26 2013-06-25 Otago Innovation Limited Antigenic compositions
CA2516339A1 (en) * 2003-02-19 2004-09-02 Takeda Pharmaceutical Company Limited Dispersing agent for sustained-release preparation
JP4683319B2 (ja) * 2003-02-19 2011-05-18 武田薬品工業株式会社 徐放性製剤用の分散剤
JP5103022B2 (ja) * 2004-02-13 2012-12-19 ノッド ファーマシューティカルズ， インコーポレイテッド リン酸カルシウムナノ粒子のコア、生体分子および胆汁酸を含む粒子、ならびにそれらの製造方法および治療用途
WO2005120484A1 (ja) * 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
WO2006059846A1 (en) * 2004-12-01 2006-06-08 Lg Life Sciences, Ltd. Formulation of sec1 mutated protein and method for formulation of the same
EP1931311A4 (en) 2005-08-29 2010-12-08 Tuo Jin POLYSACCHARIDE MICRO PARTICLES WITH BIOLOGICAL AGENTS: THEIR PREPARATION AND USES
EP1976551A4 (en) * 2005-12-23 2009-12-30 Altus Pharmaceuticals Inc COMPOSITIONS COMPRISING COMPLEX PROTEIN CRYSTALS BY POLYCATIONS AND PROCESSING METHOD THEREOF
FR2904219B1 (fr) * 2006-07-28 2010-08-13 Flamel Tech Sa Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant
CN101618213B (zh) * 2008-07-03 2013-01-23 武汉生物制品研究所有限责任公司 麻疹腮腺炎乙型脑炎联合减毒活疫苗及其制备方法
AU2009302111A1 (en) * 2008-10-08 2010-04-15 Immune Solutions Limited Oral vaccines for producing mucosal immunity
WO2014206857A1 (en) * 2013-06-28 2014-12-31 Universitat Autonoma De Barcelona Oil-in-water formulations of mycobacterium and uses thereof
CN103923881B (zh) * 2013-08-09 2016-04-06 北京科兴生物制品有限公司 甲肝病毒单克隆抗体及其应用
JP6395855B2 (ja) 2014-04-03 2018-09-26 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ブタ流行性下痢ウイルスワクチン
GB201716419D0 (en) 2017-10-06 2017-11-22 Univ Central Lancashire Solid composition
JP2022549216A (ja) 2019-09-23 2022-11-24 ディーディーエス リサーチ インク． 浸透促進剤を含有する脂質ベシクル組成物
CN112933044A (zh) * 2020-12-17 2021-06-11 太阳雨林（厦门）生物医药有限公司 一种用于恶性肿瘤治疗的载药油制剂及制备方法和应用
CN112961221B (zh) * 2021-02-28 2022-05-17 长春祈健生物制品有限公司 一种水痘-带状疱疹病毒糖蛋白e胞外区蛋白的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
JPH01287041A (ja) 1988-05-13 1989-11-17 Rooman Kogyo:Kk 徐放性製剤
JP2513276B2 (ja) 1988-06-10 1996-07-03 日本電気株式会社 位相同期ル―プ
US5416017A (en) 1990-05-18 1995-05-16 The Scripps Research Institute Cholera toxin gene regulated by tissue-specific promoters
DE4107153A1 (de) * 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
ES2110980T3 (es) 1990-11-06 1998-03-01 Inst Nacional De Engenharia E Composiciones liposomicas y procedimientos para su produccion.
AU1442592A (en) * 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
DK0726761T3 (da) * 1993-11-03 2001-06-18 Isomed Inc Mikropartikulære farmaceutiske præparater på micel-form
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
KR100201352B1 (ko) 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
WO1998013024A2 (en) 1996-09-27 1998-04-02 Hyal Pharmaceutical Corporation Hyaluronic drug delivery system
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US20020106368A1 (en) * 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same

Also Published As

Publication number Publication date
MY125541A (en) 2006-08-31
EP1071407A4 (en) 2009-05-20
CN1293568A (zh) 2001-05-02
EP1071407B1 (en) 2014-07-23
TWI260988B (en) 2006-09-01
NZ506975A (en) 2004-01-30
CA2324403A1 (en) 2000-07-20
CA2324403C (en) 2005-12-13
DK1071407T3 (da) 2014-10-20
JP3802348B2 (ja) 2006-07-26
BG104742A (en) 2001-07-31
CN1142772C (zh) 2004-03-24
ID25592A (id) 2000-10-19
PL342967A1 (en) 2001-07-16
AU3080500A (en) 2000-08-01
TR200002683T1 (tr) 2000-12-21
EP1071407A1 (en) 2001-01-31
PL200954B1 (pl) 2009-02-27
AU751200B2 (en) 2002-08-08
BG65233B1 (bg) 2007-09-28
ES2505696T3 (es) 2014-10-10
HUP0101040A2 (hu) 2001-08-28
IL138468A0 (en) 2001-10-31
HK1036415A1 (en) 2002-01-04
WO2000041682A1 (en) 2000-07-20
HUP0101040A3 (en) 2005-11-28
BR0004152A (pt) 2000-11-21
JP2002534459A (ja) 2002-10-15
EP2481401A1 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
AR043272A1 (es) Una microparticula recubierta con una sustancia lipofilica que contiene una droga proteica o antigeno y formulaciones que la comprenden
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
AR020288A1 (es) Emulsion aceite en agua que comprende un agente biologicamente activo micronizado y un sistema emulsionante adecuado.
DE69831511D1 (de) Mikropartikel zum transport von arzneistoffen durch die schleimhaut und die blut-hirn-schranke
ES2143172T3 (es) Microemulsiones desinfectantes.
NO20010264D0 (no) Bionedbrytbare preparater for kontrollert frigivelse av innkapslede stoffer
DE69305328D1 (de) Mikrokapseln mit wänden aus primären alkoholfunktionen enthaltenden polysacchariden, und zusammensetzungen daraus
ATE415943T1 (de) Pharmazeutische zubereitungen enthaltend einen amphoteren emulgator, polyproxylierten cetylalkohol und einen polaren wirkstoff
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
IL101241A (en) Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
DE59909759D1 (de) Emulgatorfreie und bornitrid enthaltende feindisperse systeme vom typ öl-in-wasser und wasser-in-öl
NZ501950A (en) Medicinal compositions for application to mucosa
AR008355A1 (es) COMPOSICIoN FARMACÉUTICA PARA ADMINISTRACIoN ORAL, USO, CREMA FARMACEUTICA PARA ADMINISTRACIoN TOPICA Y SUSPENSIoN LIQUIDA PARA ADMINISTRACIoN ORAL.
AR006087A1 (es) Forma de dosificación para la administración de clorhidrato de verapamil a una velocidad de liberación uniforme.
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
DE69912262D1 (de) Retinolhaltiges arzneimittel kompatibel mit weichgelatinekapseln
HK1038310A1 (en) Compositions and methods for treating intracellular infections.
DE60018629D1 (de) Carbamazepinformulierung mit verzögerter Freigabe
WO2001005362A3 (de) Emulgatorfreie feindisperse systeme vom typ wasser-in-öl
SE9704400D0 (sv) Porous inorganic particles as carriers for drug substances
BR0112689A (pt) Composição herbicida
BR0208865A (pt) Aplicador para aplicação de agente benéfico sobre os dentes e uso de um aplicador
UY26503A1 (es) " forma de dosificación de fármacos accionada por un hidrogel"
UA36813A (uk) Збір для лікування серцевих неврозів, стресових станів, гіпертонічної хвороби, радіофобії (лон-5)
GT199600070A (es) Composicion de gel cosmetica teniendo irritacion de la piel reducida.

Legal Events

Date Code Title Description
FG Grant, registration